McKesson (MCK) Set to Announce Earnings on Wednesday

McKesson (NYSE:MCK) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $7.09 per share for the quarter. McKesson has set its FY25 guidance at $31.75-32.55 EPS and its FY 2025 guidance at 31.750-32.550 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 7th. The company reported $7.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.21 by $0.67. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The business had revenue of $79.28 billion for the quarter, compared to analysts’ expectations of $82.53 billion. During the same quarter in the previous year, the firm posted $7.27 EPS. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, analysts expect McKesson to post $32 EPS for the current fiscal year and $35 EPS for the next fiscal year.

McKesson Price Performance

Shares of MCK stock opened at $499.18 on Wednesday. The company’s fifty day simple moving average is $514.90 and its two-hundred day simple moving average is $550.92. McKesson has a 1 year low of $431.35 and a 1 year high of $637.51. The stock has a market capitalization of $64.86 billion, a price-to-earnings ratio of 22.30, a PEG ratio of 1.18 and a beta of 0.44.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, October 1st. Investors of record on Monday, September 2nd were paid a $0.71 dividend. This is an increase from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend was Friday, August 30th. McKesson’s dividend payout ratio is presently 12.69%.

Insider Buying and Selling

In related news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $626.03, for a total value of $2,349,490.59. Following the sale, the chief executive officer now owns 82,339 shares in the company, valued at approximately $51,546,684.17. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.11% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MCK. Mizuho raised their target price on shares of McKesson from $540.00 to $570.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. raised their target price on shares of McKesson from $656.00 to $661.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Citigroup decreased their target price on shares of McKesson from $670.00 to $630.00 and set a “buy” rating for the company in a research note on Tuesday, September 10th. StockNews.com downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Evercore ISI decreased their target price on shares of McKesson from $660.00 to $630.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $610.86.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.